Company will leverage its proprietary vIgDTM platform using directed evolution to create novel, multi‐functional first in class immunotherapies SEATTLE, Wash., June 13, 2016 – Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next‐generation immune system